Assoc. Prof. Marcela Viviana Karpuj

mvkarpuj@braude.ac.il

04-9901895

D215

מחלקה: Biotechnology Engineering

תפקיד נוכחי: Associate Professor

Research Interests

1. Neurodegenerative (NDS) and infectious diseases
2. Personalized Medicine
3. Drug delivery (nanoparticles and BBB)
4. The Genetic, environmental and character attributes and their influence on NDS
5. Membrane protein in health and disease
6. Anti-cancer drug screening utilizing a novel loss-of-function technology

Courses

1. Biotechnology engineering
2. Scientific writing
3. Molecular Biology (laboratory)
4. Biochemistry I (Course and Laboratory)
5. Advanced genetic engineering (B.Sc)

Experience in Preclinical Drug Development

BIOA2Z, Inc.

Founder and CEO of a preclinical anti-cancer personalized drug development program
- Established a novel loss of function technology to target specific oncogene variants.
- Adapted a high-throughput screening (HTS)
- Antibody design and purification

CUBRC, Inc.

Co-director of preclinical antiviral drug development program
- Established protein purification systems in cell-free translation and mammalian cells.
- Protein purification systems and analysis of biophysical properties
- Antibody design and purification
- Designed, tested, and performed troubleshooting on a novel assay for viral capsid assembly inhibitors.
- Adapted assay for HTS.
- Directed statistical analysis of HTS leads.
- Validated secondary screening for lead compounds.
- Assisted in finding small molecule active site.
- Validation of active compound in vitro and animal models
Awarded Defense Threat Reduction Agency (US DoD) Contract “Transformational Medical Technologies Initiative – “Broad Spectrum Blockade of Hemorrhagic Fever Virus Capsid Assembly – Ebola, Rift Valley Fever & Lassa Fever Viruses” $8,300,000.
Designed HTS strategy.
Opened new avenues and create collaborations for non-human anti-viral HTS.
Managed and developed full-time direct reports and new to industry interns.
Negotiated numerous business agreements with 3^rdThe niversity of California San Francisco.

Revealed the involvement of Phosphorothioate in Prion disease in vitro and in vivo. Stanford University.

Discovered the involvement of transglutaminase in neurodegenerative diseases, including Multiple Sclerosis and Huntington’s disease, both in cell culture and in animal models.

Non-Academic previous positions

Science & Business     2008 to 2012

Consultant                   Spyglass biosecurity, Chemical, mBio Diagnostics, and Neurion Pharmaceuticals. Conducted marketing, operation, financial analysis, and scenario planning.

Research Director       2006 to 2009

Principal Scientist        CUBRC Inc, Buffalo, New York. Established an HTS assay for anti-viral drug screening utilizing immunological and biochemical tools. Developed a revolutionary new generation of drugs for the treatment of viral diseases caused by biological terrorism-relevant threat agents such as Ebola, HANTAN, and Rift Valley Fever Virus. Studied protein bio conformers’ effect on the immune response to different Ebola glycoproteins.

CEO and Founder       2011 to 2017

BioA2Z Inc, San Francisco, CA, USA. Manage academic and industrial collaboration to support the development of the proprietary technology for membrane protein regulation associated with cancer and neurodegenerative disorders. In charge of the 2012 company Incorporation, Intellectual property litigation, business plan creation, revenue projections, and market analysis.

Scholarships,

2024: Prize for an outstanding faculty member at the Department of Biotechnology Engineering Braude College, Karmiel.

PI (Principal Investigator) Co-Researchers: Dr. Hussein Naseraldin, Professor Wertheim Rafi, Dr. Malka Nir Topic: From academic research to translational implementation. Funded by/Amount: Ministry of Innovation, Science, and Technology – 75,000 INS Year: 2022

2022: Prize for an outstanding faculty member at the Department of Biotechnology Engineering Braude College, Karmiel.

2021: Prize for an outstanding faculty member at the Department of Biotechnology Engineering Braude College, Karmiel.

2020: Prize for an outstanding faculty member at the Department of Biotechnology Engineering Braude College, Karmiel.

2020: Award-winning at the first National Hacktau competition at the Tel Aviv University Entrepreneurship Center. Winning team award among all academic teams and winning team award of the entire competition including all academic and industry teams.

2010: Prize for outstanding achievements, Nucleic acid research, and Oxford Journal.

2003-2004: 'Best Teacher' at the Department of Biochemistry and Nutrition in the Faculty of Agriculture, Hebrew University of Jerusalem.

1995: Ph.D. Scholarship award, Feinberg Graduate School, Weizmann Institute of Science

1995: M.Sc. in Biochemistry, Cum Laude

Awards and Prizes

Teaching

*2017 present: Biochemistry I. Braude College (Lecturer) – Lecture. Transformed the entire course into a hybrid course with videos and exercises for all topics. (B.Sc.)

*2017-present: Biochemistry. Braude College (Laboratory) – Lab principal instructor. (B.Sc.)

*2017-present: Advanced methods in genetic engineering. Braude College (Lecturer) – Lecture. (M.Sc.)

*2017-2021: Scientific writing. Braude College (Lecturer) – Lecture. (B.Sc.)

*2017-2018: Molecular Biology. Braude College (Laboratory) – Lab instructor. (B.Sc.)

*2017-2018: Biotechnology Engineering. Braude College (Lecturer) – Lecture. (B.Sc.)

*2017: Methods in separation (Laboratory) – Lab Instructor. (B.Sc.)

2016: Controlling Gene Expression in Health and Disease. Faculty of Agriculture (Guest Lecturer) – Lecture. (M.Sc. and Ph.D.)

2003-2004: neurodegenerative diseases and Nutrition. Faculty of Agriculture (Lecturer) – Lecture. (M.Sc. and Ph.D.)

2003-2004: Biochemistry Faculty of Agriculture. (Lecturer) – Mandatory Course/Lab. (M.Sc.)

Year	Funded by/ Amount	Topic	Researchers PI /Co	Role in Research
2004	Hebrew University: Innovative Ideas Grant – $20,000	First steps toward understanding the natural transmission route in prion diseases	Professor Oded Shoseyov, Hebrew University, Faculty of Agriculture (Co-PI)	PI
2004-2005	Bi-National Science Foundation (BSF) Grant – $59,206	Diagnostic biomarkers for humans and animals producing prions	Professor Stanley Prusiner, UCSF, USA (Co-PI)	PI
2006-2008	Defense Threat Reduction Agency (US DoD) Contract “Transformational Medical Technologies Initiative" – $8,300,000	Broad spectrum blockade of hemorrhagic fever virus capsid assembly – Ebola, Rift Valley Fever & Lassa Fever Viruses	Professor Vishu Lingappa, CPMC, San Francisco, CA (PI), and Dr. Christopher Davis, CUBRC, Inc. (Co-PI)	PI
2013	National Science Foundation – $150,000	Innovative drug development kit platform for advanced cancer therapy	Professor Zena Werb, UCSF (Co-PI), and Professor Lawrence Steinman, Stanford University (Co-PI)	Co-PI

2014	MAGNET – $300,000	Equipment grant	Dr. Itay Onn, Faculty of Medicine (Co-PI)	PI
2015	Israeli Ministry of Science – $30,000	Characteristics of coronary and systemic circulations with blood cell subpopulations	Prof. Ofer Amir, Poria Hospital (PI)	Co-PI
2023	Collaborative research initiative Tel-Hai, MIGAL, and Braude – 50,000 INS	Innovative Platform for Neurodegenerative Therapies Modelling and Drug Development	Professor David Karasik, Faculty of Medicine (Co-PI), Dr. Karen Jackson and Dr. Paula Pitashny, MIGAL TEL-HAI (Co-PI)	PI

Date	Name of Institution and Department	Type of Presentation	Title/Comments
June 2011	Tel Aviv University, Israel	Colloquium Talk	Short Phosphorothioate Oligonucleotides-Potential Therapeutic Agent for Prion Diseases/ Invited Lecturer
May 2013	Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile	Colloquium Talk	Prion therapy in animal models leads to a novel research tool to advance translational medicine/ Invited Lecturer
April 2015	Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Universidad de Oviedo, Spain	Colloquium Talk	Applications of a novel loss of function tool for basic research and personalized medicine/ Invited Lecturer
September 2023	Medical and Pharmacology school, Haiphong, Vietnam	Colloquium Talk	The Combination of Models and New Technologies to Combat Infectious and Aging Diseases/ Invited Lecturer
September 2023	Medical and Pharmacology school, Haiphong, Vietnam	Scientific Writing Invited Workshop	Writing a winning abstract/ Invited Lecturer

International Active Participation

Date	Name of Conference	Place of Conference	Subject of Lecture	Role
August, 1998	Hereditary Disease Foundation	Cape Cod, Massachusetts	Non-amyloid aggregates in Huntington’s Disease brain	Invited Lecturer
August, 1999	Hereditary Disease Foundation	Cambridge, Massachusetts	Transcriptional profile of HD brain with microarrays reveals coordinated patterns of regulation in response to a lethal mutant gene	Invited Lecturer
October, 1999	Society for Neuroscience	Miami Beach, Florida	Transcriptional profile of Huntington’s Disease brain with gene microarrays	Invited Lecturer
March, 2000	Society of Neurochemistry	Chicago, Illinois	Transglutaminase aggregates Huntingtin into non-amyloidogenic polymers and its enzymatic activity is increased in Huntington’s Disease brain nuclei	Invited Lecturer
August, 2000	Hereditary Disease Foundation	Cambridge, Massachusetts	Prolonged survival and reversal of abnormal movements in Huntington’s Disease.	Invited Lecturer
January, 2000	Altered Gene Expression in Neurological and Neuropsychiatric Diseases	Cambridge, Massachusetts	Cystamine, a competitor for Transglutaminase, slows the progression of Huntington’s Disease in a transgenic mouse model without altering formation of nuclear inclusions	Invited Lecturer
October, 2000	The New Prion Biology	Sardinia, Italy	Gene microarray as a new tool for research and diagnosis in Parkinson’s disease and other neurodegenerative disorders	Key-Note Speaker
January, 2000	Altered Gene Expression in Neurological and Neuropsychiatric Diseases	Cambridge, Massachusetts	Cystamine, a competitor for Transglutaminase, slows the progression of Huntington’s Disease in a transgenic mouse model without altering the formation of nuclear inclusions	Invited Lecturer
October, 2000	The New Prion Biology	Sardinia, Italy	Gene microarray as a new tool for research and diagnosis in Parkinson’s disease and other neurodegenerative disorders	Key-Note Speaker
January, 2002	Microarrays, Models and Mechanisms	Seattle, Washington	Microarray for neurodegenerative diseases	Invitation-Only Selective Workshop
April, 2002	The New Prion Biology	Sardinia, Italy	Elimination of Scrapie prions and diminished cellular prion expression by phosphorothioate oligonucleotides	Invited Lecturer
December, 2002	Therapeutic Opportunities in Neurodegenerative diseases	Cold Spring Harbor, NY	Targeting cellular prion expression with Phosphorothioate oligonucleotides reduce PrP^C while eliminating PrP^Sc	Invited Lecturer
July, 2003	Human Frontiers	Cambridge, UK	Short Phosphorothioate oligonucleotides reduces PrP^C while eliminating PrP^Sc	Invited Lecturer
June, 2008	Bridge to Biotech, Biomanufacturing	City College, San Francisco, USA	Bridge to Biotech	Invited Lecturer



June, 2008	Bridge to Biotech, Biomanufacturing	City College, San Francisco, USA	Bridge to Biotech	Invited Lecturer
February, 2006	Amino Acids	Rome, Italy	Prolonged survival and reversal of abnormal movements in Huntington’s disease in a transgenic mouse model, after administration of Cystamine, a transglutaminase inhibitor	Invited Lecturer
October, 2010	Oligonucleotide Therapeutics Society, The 6^th Annual Meeting	Dana Point, CA, USA	A novel method for membrane protein degradation in cell culture mediated by oligodeoxynucleotides	An outstanding award Poster which was chosen for a short presentation
November, 2012	Zing Neurodegeneration Conference	Mexico	A Novel Method for Membrane Protein Regulation in Cell Culture	Invited Lecturer

May 2018	Prion 2018 Conference	Santiago de Compostela, Spain	Phosphorothioate oligonucleotides: From a possible prion therapy to a novel loss of function tool	Poster Presentation
June 2018	Gordon Research Conference Transglutaminase in Human Disease Processes	Les Diablerets, Switzerland	“Lost in translation”: A TGAse inhibitor advances from preclinical to clinical trials phase II/III and gets to its (hopefully temporary) endpoint.	Poster Presentation


October 2018	Biomedical Engineering Society	Atlanta, Georgia, USA	A qPCR Based assay for detecting Mycoplasma contamination in cell lines	Poster Presentation
November 2021	Society for Neuroscience	Chicago, Illinois, USA	The Potential Impact of Zero Gravity on Amyloid Aggregation	Poster Presentation
September 2023	TechConnect and Innovation conference, TechConnect and Innovation conference, Ministry of Science and Technology	Quang Ninh Exhibition of Planting and Expo Center. Vietnam	The Combination of Models and New Technology to Combat Infectious and Aging Diseases.	Special guest invitation for Oral Presentation.
October 2023	Prion 2023 Conference	Faro, Portugal	A Novel Therapeutic Approach Modulates Protein Interactions and Cellular Processes.	Abstract chosen for Oral Presentation.
November 2023	, 3^rd International Conference on Microbiology and Infectious Diseases	Dubai, UAE	Comparative Bioinformatic Analysis Identifies Conserved Regions for Enhanced Detection and Therapeutics Targeting of SARS-Cov-2 and Future Pandemics.	Keynote Presentation.
April 2024	Point of Care Diagnostics	Leipzig, Germany	The importance of Point of Care Diagnostics- Leveraging what we have learned from COVID-19 to future pandemics.	Keynote Presentation

National Active Participation

March 2014 HFSP Alumni Meeting, Weizmann Institute of Science, Israel. Adaptation of a novel loss of function technology for membrane proteins to cancer research Selected for oral presentation at the opening session. Oral Lecture.

January 2003 Hereditary Disease Foundation Weizmann Institute, Israel. Reduction of aggregates in neurodegenerative diseases leads to possible therapies and raises new questions. Oral Lecture.

Dates	Name of Institution and Department	Rank/Position
1993-1999	Hebrew University, Faculty of Agriculture, Department of Biochemistry	Teaching and Research Assistant
1997-2000	Stanford University, Department of Neurology at the laboratory of Professor Lawrence Steinman.	Postdoctoral Research Fellow
2000-2003	University of San Francisco California, Department of Neurology and Infectious Diseases at the laboratory of Professor Stanley Prusiner.	Postdoctoral Research Fellow
2003-2006	Hebrew University, Faculty of Agriculture, Department of Biochemistry	Lecturer (Tenure track)
2006-2007	CUBRC Inc, Buffalo, New York.	Director of Research, Principal Scientist (unpaid vacation from the Faculty of Agriculture)
2008-2009	Buffalo University, The State University of New York, Department of Microbiology and Immunology	Assistant Research Professor
2012-2013	University of California, San Francisco, Department of Anatomy	Visiting Scientist
March 2017-October 2017	ORT Braude College, Department of Biotechnology Engineering	Adjunct Lecturer
October 2017-Present	ORT Braude College, Department of Biotechnology Engineering	Senior Scientist
October 2024-Present	Braude College of Engineering, Department of Biotechnology Engineering	Associate Professor

Offices in Academic Administration

March 2023 12th Braude Industry-Academy Conference Braude Karmiel Academia-Industry – From academic research to translational implementation Head of the Organizing Committee, opening and closing of the Conference and Chair of the Startup panel.

*March 2022 11th Braude Industry-Academy Conference Virtual Conference Academia-Industry – Opportunities & Challenges Head of the Organizing Committee, and Chair of all sessions.

*February 2021 10th Braude Industry-Academy Conference Virtual Conference Challenges & Insights in Times of Crisis Head of the Organizing Committee, and Chair of all sessions.

*October 2018 Braude Interdisciplinary Conference Kfar Blum Braude Interdisciplinary Conference Part of the organizing committee.

*October 2018 Braude Interdisciplinary Conference Kfar Blum Braude Interdisciplinary Conference Chair at the Cognitive Processes and Virtual Reality session.

*March 2022 11th Braude Industry-Academy Conference Virtual Conference Academia-Industry – Opportunities & Challenges- Moderator, and leader of the final panel discussion.

*February 2021 10th Braude Industry-Academy Conference Virtual Conference Challenges & Insights in Times of Crisis- The crisis as an engineering and entrepreneurial accelerator in Israeli industry Moderator, and leader of the final panel discussion.

*October 2018 Braude Interdisciplinary Conference Kfar Blum The discovery of a possible prion therapy leads to a novel loss of function Chair and Lecturer.

*January 2021-Present Committee of academic affairs member, the Biotechnology Engineering Departmental, Braude College, Karmiel.

*January 2021-Present Committee on Academic Computing and Information Systems member, Braude College, Karmiel.

*April 2021-Present Departmental faculty recruitment Committee member, the Biotechnology Engineering Departmental, Braude College, Karmiel.

*April 2020-Present Head of the Yearly Academia Industry Conference Committee.

*April 2020-Present Member of the Volunteering IT Support Team as part of the COVID-19 Emergency Response Effort at Braude College, Karmiel.

*April 2019-Present Safety Committee member, the Biotechnology Engineering Departmental, Braude College, Karmiel.

*April 2019-Present BSL2 Tissue Culture Manager, Braude College, Karmiel.

*April 2018-2021 Animal Facility Head, Braude College, Karmiel.

*April 2018-2021 Animal ethics committee chair, Braude College, Karmiel.

*November 2018-Present Academic Authority Head in charge of the Biotechnology Engineering, Departmental Website Content.

2016-October 2017 Member of the Bioinformatics Committee, Faculty of Medicine, Bar Ilan University, Safed.

2015-October 2017 Member of the Genome Technology Committee, Faculty of Medicine, Bar Ilan University, Safed.

2014-October 2017 Head of Technology Genome Centre, Faculty of Medicine, Bar Ilan University, Safed (permanent position).

Scientific Consultation

*2022-present Laboratory of Prof. Yarden, Department of Immunology and Biological Regulation, the Weizmann Institute of Science.

*2019-2022 Laboratory of Prof. Gross, Department of Biological Regulation, the Weizmann Institute of Science.

2015-2018 Laboratory of Prof. Lapidot, Department of Immunology, the Weizmann Institute of Science.

2015-2017 Orot Luses, Impact investment fund focusing on cancer innovation.

Undergraduate and Graduate Studies

Year of Approval of Degree Degree Name of Institution
and Department Period of Study
1993 B.Sc. The Hebrew University, Department of Chemistry 1991-1993
1995 M.Sc. (Cum Laude) The Hebrew University, Faculty of Agriculture, Department of Biochemistry 1993-1995
1999 Ph.D. The Weizmann Institute, Department of Immunology 1995-1999
2011 MBA in Sustainability (Summa Cum Laude), (GPA 3.8/4) Alliant International University Presidio Graduate School: San Francisco, CA, US 1999-2011

Post-Doctoral Studies

Period of Study Name of Institution Department and Host Degree Year of Completion
1998-2000 Stanford University, Department of Neurology (Professor Lawrence Steinman) Postdoctoral Research Fellow 2000
2000-2003 University of San Francisco, California, Department of Neurology and infectious diseases, (Nobel Laureate, Professor Stanley Prusiner) Postdoctoral Research Fellow 2003

Competitive External Training Courses

European Molecular Biology Organization Course for Principal Investigators: November 2005. Laboratory Management Course for Young Principal Investigators.
Cold Spring Harbor Post-Doctoral Course: November 2002. First Course in Proteomics.
Cold Spring Harbor Ph.D. Course: August 1997. Neurobiology of Disease.

Ph.D. Dissertation
‘Evidence from biochemical, molecular biological and gene micro-array analysis indicates involvement of transglutaminase and ubiquitin-related proteins in the pathogenesis of Huntington’s Disease ‘. Weizmann Institute of Science, Israel. Supervisor: Professor Lawrence Steinman. Submitted: May 1999; Language: English.

Articles in Refereed Journals and patents

Note: Each publication will be accompanied by the following information: Registered in JCR (V), Impact Factor (IF), Rank/Number of Journals in the list, Name of specialty list (I- Initiator of the study; II- Performing the study; III-Writing the manuscript draft; IV-Reviewing the draft).

1. Karpuj V M., Shaytov D R., Shemer-Avni Y., Gidon M., Frenkel Z M., Sivan S. (2024) Comparative Bioinformatic Analysis Reveals Conserved Regions in SARS-CoV-2 Genome for RAPID Pandemic Response. International Journal of Molecular Sciences. (Invited to submit the manuscript by the editor for a special edition- accepted).

V, IF: 5.6, Q1 Biochemistry and Molecular Biology, Rank: 66/285 Biochemistry and Molecular Biology, Contribution: I-IV

2. Grinberg L, Dabbah Assadi F, Baum G, Zemel R, Tur-Kaspa R, Shochat C, Karasik D, Karpuj V M. (2023) Beneficial effect of vitamin D on Non-Alcoholic Fatty Liver Disease (NAFLD) progression in the Zebrafish model. Nutrients. 15, 1362 (Invited to submit the manuscript by the editor for a special edition).

V, IF: 5.7, Q1 Food Science, Rank: 15/131 Nutrition & Dietetics, Contribution: II-IV

3. Palandel V., Raviv D., Karpuj V M., Rainer G., Morgenstern M. (2022) Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients – an avenue for clinically relevant diagnostic analysis. Molecular Oncology. 16, 2098-2114.

4. Wahbeh H, Radin D, Yount G, Woodley M A., Sarraf M A, Karpuj M V. (2022) Genetics of psychic ability – A pilot case-control exome sequencing study. Explore- The Journal of Science and Healing. 18, 264-271.

V, IF:2.4, Q2 Behavioral Neuroscience, Rank 21/30 Integrative &Complementary Medicine, 1 Citation, Contribution: II-IV

5. Wahbeh H, Radin D, Yount G, Woodley M A., Sarraf M A, Karpuj M V. (2022) Genetics of psychic ability – A pilot case-control exome sequencing study. Explore- The Journal of Science and Healing. 18, 264-271.

V, IF:2.4, Q2 Behavioral Neuroscience, Rank 21/30 Integrative &Complementary Medicine, 1 Citation, Contribution: II-IV

6. Tabouy L., Getselter D., Ziv O., Karpuj M., Tabouy T., Werbner N., Ben-Amram H., Nuriel-Ohayon M., Koren O., Elliott E. (2018) Dysbiosis of microbiome and probiotic treatment in a genetic model of autism spectrum disorders. Brain Behavior and Immunity. 73, 310-319.

V, IF:19.3, Q1 Immunology, Rank: 10/162 Immunology, 78 Citations, Contribution: II-IV

7. Takai, K., Drain, A. P., Lawson, D. A., Littlepage, L. E., Karpuj, M., Kessenbrock, K., Le, A., Inoue, K., Weaver, V. M., Werb, Z. (2018). Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancers. Genes and Development. 32, 244-257.

V, IF:12.9, Q1 Developmental Biology, Rank: 23/195 Cell biology, 34 Citations, Contribution: II-IV

8 .Journo, G., Tushinsky, C., Shterngas, A., Eran, Y., Karpuj, M.V., Frenkel-Morgenstern, M., and Shamay, M. (2018) Modulation of Cellular CpG DNA Methylation by Kaposi's Sarcoma Associated Herpesvirus. Journal of Virology. 98, 8-18.

V, IF:6.6, Q1 Immunology, Rank: 8/38 Virology, 12 Citations, Contribution: I- IV

9. Broce, S., Hensley, L., Sato, T., Lehrer-Graiwer, J., Essrich, C., Edwards, K.J., Pajda, J., Davis, C.J., Bhadresh, R., Hurt, C.R., and Karpuj, M. (2016). Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals. Biology Direct. 11, 25.

V, IF:7.2, Q1 Agricultural, and Biological Sciences, Rank: 11/94 Biology, 3 Citations, Contribution: I- IV

10. Van Strien, M.E., de Vries, H.E., Chrobok, N.L., Bol, J.G.J.M., Breve, J.J.P., van der Pol, S.M.P., Kooij, G., van Buul, J.D., Karpuj, M., Steinman, L., et al. (2015). Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. Brain Behavior and Immunity. 50, 141–154.

V, IF:19.3, Q1 Behavioral Neuroscience, Rank: 6/275 Neurology, 23 Citations, Contribution: I- IV

11. Nardone, S., Sams, D.S., Reuveni, E., Getselter, D., Oron, O., Karpuj, M., and Elliott, E. (2014). DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. Translational Psychiatry. 4, e433.

V, IF:8, Q1 Biological Psychiatry, Rank: 24/155 Psychiatry, 155 Citations, Contribution: II, IV

12. Ben-Gedalya, T., Lyakhovetsky, R., Yedidia, Y., Bejerano-Sagie, M., Kogan, N.M., Karpuj, M.V., Kaganovich, D., and Cohen, E. (2011). Cyclosporin-A-induced prion protein aggresomes are dynamic quality-control cellular compartments. Journal of Cell Science. 124, 1891–1902.

V, IF:5.2, Q1 Cell Biology, Rank: 87/195 Cell Biology, 27 Citations, Contribution: II, IV

13. Karpuj, M.V., Gelibter-Niv, S., Tiran, A., Rambold, A., Tatzelt, J., Nunziante, M., and Schatzl, H.M. (2011). Conditional modulation of membrane protein expression in cultured cells mediated by prion protein recognition of short phosphorothioate oligodeoxynucleotides. Journal of Biological Chemistry. 286, 6911–6917.

V, IF:5.5, Q1 Biochemistry, Rank: 94/297 Biochemistry & Molecular Biology, 6 Citations, Contribution: I- IV

14. Karpuj, M., Smith, D., Kelley-Clarke, B., Stossel, A., Honko, A., Broce, S., Van Loan, N., Harrell, E., Kelleher, C., Lingappa, J.R., et al. (2010). Small Molecule Therapeutics of Viruses of Families Bunyaviridae and Arenaviridae. Antiviral Research. 86, A58–A58.

V, IF:10.1, Q1 Virology, Rank: 6/37 Virology, 1 Citation, Contribution: I- IV

15. Karpuj, M.V., Giles, K., Gelibter-Niv, S, Scott, M.R., Lingappa, V.R., Szoka, F.C., Peretz, D., Denetclaw, W., and Prusiner, S.B. (2007). Phosphorothioate oligonucleotides reduce PrPSc levels and prion infectivity in cultured cells. Journal of Molecular Medicine. 13, 190–198.

V, IF:5.6, Q1 Molecular Medicine, Rank: 47/139 Medicine, Research & Experimental, 27 Citations, Contribution: I- IV

16. Karpuj, M., and Steinman, L. (2004). The multifaceted role of transglutaminase in neurodegeneration: Review article. Amino Acids. 26, 373–379.

V, IF:3.8, Q2 Clinical Biochemistry, Rank: 147/297 Biochemistry & Molecular Biology, 11 Citations, Contribution: I- IV

17. Karpuj, M.V., Becher, M.W., and Steinman, L. (2002). Evidence for a role for transglutaminase in Huntington’s disease and the potential therapeutic implications. Neurochemistry International. 40, 31–36.

V, IF:4.3, Q2 Cell biology, Rank: 115/275 Neuroscience, 50 Citations, Contribution: I-IV

18. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Pedotti, R., Youssef, S., Mitchell, D., and Steinman, L. (2002). Prolonged survival and decreased abnormal movements in a transgenic model of Huntington’s disease, with the administration of the transglutaminase inhibitor Cystamine. Nature Medicine. 8, 303–303.

V, IF:31.3, Q1 Biochemistry, Rank: 4/162 Immunology, 156 Citations, Contribution: II, IV

19. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Tsai, M., Galli, S.J., and Steinman, L. (2001). An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nature Immunology. 15, A1218–A1218.

V, IF:12.3, Q1 Neurology, Rank: 9/212 Clinical Neurology, Contribution: II, IV

20 .Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Tsai, M., Galli, S.J., and Steinman, L. (2001). Allergy to self: An unexpected immune response in EAE. Neurology. 56, A94–A94.

V, IF:12.3, Q1 Neurology, Rank: 9/212 Clinical Neurology, 1 Citation, Contribution: II, IV

21. Chabas, D.E., Steinman, L., Rittling, S.R., Sobel, R., Lock, C., Mitchell, D., Pedotti, R., Karpuj, M., Heller, R., Oksenberg, J., et al. (2001). Elevated osteopontin transcripts in MS brain libraries and its role in the development of progressive versus relapsing autoimmune encephalomyelitis. Neurology. 56, A467–A467.

V, IF:63.8, Q1 history and Philosophy of Science, Rank: 2/74 Multidisciplinary Science, 878 Citations, Contribution: II, IV

22. Chabas, D., Baranzini, S.E., Mitchell, D., Bernard, C.C.A., Rittling, S.R., Denhardt, D.T., Sobel, R.A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001). The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 294, 1731–1735.

V, IF:63.8, Q1 history and Philosophy of Science, Rank: 2/74 Multidisciplinary Science, 878 Citations, Contribution: II, IV

23. 2 Karpuj, M.V., Chan, P., Di Monte, D., Langston, J.W., and Steinman, L. (2000). Gene microarray analysis of Parkinson’s disease specimens. Neurology. 54, A427–A427.

V, IF:12.3, Q1 Neurology, Rank: 9/212 Clinical Neurology, 878 Citations, Contribution: I-IV

24. Karpuj, M.V., and Steinman, L. (2000). Transglutaminase aggregates Huntingtin into Non-Amyloidogenic Polymers and its enzymatic activity is increased in Huntington’s disease brain nuclei. Journal of Neurochemistry. 74, S96–S96.

V, IF:5.5, Q1 biochemistry, Rank: 73/275 Neuroscience, Contribution: I- IV

25. Ruiz, P.J., Garren, H., Ruiz, I.U., Hirschberg, D.L., Nguyen, L.V.T., Karpuj, M.V., Cooper, M.T., Mitchell, D.J., Fathman, C.G., and Steinman, L. (1999). Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation. Journal of Immunology. 162, 3336–3341.

V, IF:5.4, Q1 immunology, Rank: 64/162 Immunology, 130 Citations, Contribution: II, IV

26. Ruiz, P.J., Garren, H., Hirschberg, D.L., Langer-Gould, A.M., Levite, M., Karpuj, M.V., Southwood, S., Sette, A., Conlon, P., and Steinman, L. (1999). Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. Journal of Experimental Medicine. 189, 1275–1283.

V, IF:17.6, Q1 Immunology, Rank: 4/139 Medicine Research &Experimental, 67 Citations, Contribution: II, IV

27. Karpuj, M.V., Garren, H., Slunt, H., Price, D.L., Gusella, J., Becher, M.W., and Steinman, L. (1999). Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington’s disease brain nuclei. Proceedings of National Academy of Science USA. 96, 7388–7393.

V, IF:12.8, Q1 Multidisciplinary, Rank: 9/74 Multidisciplinary Science, 256 Citations, Contribution: I- IV.

28. Ruiz, P.J., Wolkowicz, R., Waisman, A., Hirschberg, D.L., Carmi, P., Erez, N., Garren, H., Herkel, J., Karpuj, M., Steinman, L., et al. (1998). Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Medicine. 4, 710–712.

V, IF:87.3, Q1 Biochemistry Genetics and Molecular Biology, Rank: 1/297 Medicine, Research & Experimental, 62 Citations, Contribution: II, IV

29. Karpuj, M.V., Steinman, L., and Oksenberg, J.R. (1997). Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics. 1, 21–28.

V, IF:3, Q1 Cellular, and Molecular Neuroscience, Rank: 51/166 Clinical Neurology, 30 Citations, Contribution: III, IV

30. Tal, M., Ammar, D., Karpuj, M., Krizhanovsky, V., Naim, M., and Thompson, D. (1995). Novel Putative Neuropeptide Receptor Expressed in Neural Tissue, Including Sensory Epithelia. Biochemical and Biophysical Research Communication. 209, 752–759.

V, IF:3.3, Q1 Biophysics, Rank: 39/72 Biophysics, 113 Citations, Contribution: II-IV

Referred Proceedings

Shimon Amselem, Amselem, S., Marmur, Y., Szenkier, N., Navon, A., Gross, A., Steinman, L., Rothbard, J., & Karpuj, M. V. (2022). The combinatorial effect of chronic drug intake and microgravity on Amyloid formation. Prion 2022 Conference abstracts: pushing the boundaries. Prion, 16, 95–253

V, IF: 2.1, Q3 Biochemistry, Contribution: I-IV

Drain, A. P., Takai, K., Lawson, D. A., Littlepage, L. E., Karpuj, M., Kessenbrock, K., Le, A., Inoue, K., Weaver, V. M., & Werb, Z. (2018). Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancer. American Association for Cancer Research, 78, LB-055-LB-055

V, IF:9.4, Q1 Developmental Biology, Rank: 14/181 Cell biology, Contribution: II, III, IV

Zemel, R., Rapaport, N., Perez, S., Kitayner, M.E., Morad, E., Karpuj, M., Ravid, A., Frenkel-Morgenstern, M., Gal-Tanamy, M., Haviv, I., et al. (2016). Vitamin D antagonizes the expression of genes that are epigenetically regulated by the Hepatitis C virus. 64, 740A–741A.
IF:17.3, Q1 Hepatology, Rank: 4/79 Gastroenterology and Hepatology-SCIE. Contribution: II
Rapaport, N., Zemel, R., Morad, E., Wynstein, D., Karpuj, M., Ravid, A., Haviv, I., and Tur-Kaspa, R. (2016). Transcriptomic Antagonism Between HCV Infection and Vitamin D. Hepatology. 64, S421–S421.
IF:11.7, Q1 Hepatology, Rank: 4/79 Gastroenterology and Hepatology-SCIE. Contribution: II

Assoc. Prof. Marcela Viviana Karpuj

Assoc. Prof. Marcela Viviana Karpuj

ייעוץ לימודים